Literature DB >> 20348880

Notch1 in primary effusion lymphoma: a clinicopathological study.

Huan-You Wang1, Franklin S Fuda, Weina Chen, Nitin J Karandikar.   

Abstract

Primary effusion lymphoma is a human herpes virus 8 (HHV-8)-associated large cell lymphoma of body cavities. Detailed large-scale clinicopathological studies are rarely reported, and the underlying mechanism of lymphomagenesis remains elusive. In the present report, we studied the clinicodemographic, immunophenotypic, and cytomorphological features on a cohort of 12 cases of primary effusion lymphoma. In contrast to HHV-8, which was positive in all nine cases tested (100%), HIV was found in 75% (9/12) of cases, whereas the three HIV-negative cases were either in elderly patients (one with hepatitis C virus infection and one with asbestoses exposure) or in a heart transplantation recipient. By flow cytometry, the antigens expressed in descending order were CD38, CD71, HLA-DR, CD30, and CD45RO. B-cell markers were largely negative. Cytomorphologically, all cases showed atypical to anaplastic morphology. Notch1, a member of transmembrane signal transduction family, was found in six of seven HHV-8-positive cases (86%). In agreement with in vitro studies using human primary effusion lymphoma cell lines, we have found that Notch1 was expressed in the majority of HHV-8-positive primary effusion lymphoma cases, corroborating the notion that Notch1 may have an important role in HHV-8-mediated lymphomagenesis of primary effusion lymphoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348880     DOI: 10.1038/modpathol.2010.67

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.

Authors:  William R Foster; Alina Bischin; Russell Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01

2.  Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma.

Authors:  Genevieve M Crane; Rena R Xian; Kathleen H Burns; Michael J Borowitz; Amy S Duffield; Janis M Taube
Journal:  J Cutan Pathol       Date:  2014-12-08       Impact factor: 1.587

3.  Nodal involvement by marginal zone B-cell lymphoma harboring t(14;22)(q32;q11) involving immunoglobulin heavy chain and light chain lambda as the sole karyotypically recognizable abnormality in a patient with systemic lupus erythematosus.

Authors:  Ke Li; Rebecca L Johnson; Shiyong Li; John A Thorson; Carolyn M Mulroney; Marie L Dell'Aquila; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

4.  A Unique Case of Malignant Pleuropericardial Effusion: HHV-8-Unrelated PEL-Like Lymphoma-A Case Report and Review of the Literature.

Authors:  Farhan Mohammad; Muhammad Neaman Siddique; Faraz Siddiqui; M Popalzai; Masoud Asgari; Marcel Odaimi
Journal:  Case Rep Oncol Med       Date:  2014-03-04

Review 5.  Classic KSHV/HHV-8-positive Primary Effusion Lymphoma (PEL): A Systematic Review and Meta-Analysis of Case Reports.

Authors:  Ilaria Cozzi; Giovanni Rossi; Emma Rullo; Valeria Ascoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-03-01       Impact factor: 2.576

Review 6.  Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Authors:  Wojciech Szlasa; Jakub Czarny; Natalia Sauer; Katarzyna Rakoczy; Natalia Szymańska; Jakub Stecko; Maksymilian Kołodziej; Maciej Kaźmierczak; Ewa Barg
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

7.  Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.

Authors:  Junghoon Shin; Jeong-Ok Lee; Ji-Young Choe; Soo-Mee Bang; Jong-Seok Lee
Journal:  Cancer Res Treat       Date:  2016-06-10       Impact factor: 4.679

8.  Primary effusion lymphoma in human immune deficiency (HIV)-negative non-organ transplant immunocompetent patients.

Authors:  Lisi Yuan; James R Cook; Tarik M Elsheikh
Journal:  Diagn Cytopathol       Date:  2019-12-17       Impact factor: 1.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.